NextCure (NXTC) Competitors

Actinium Pharmaceuticals (NYSE:ATNM) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Does the MarketBeat Community favor ATNM or NXTC?

NextCure received 71 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 65.08% of users gave NextCure an outperform vote while only 47.83% of users gave Actinium Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Actinium Pharmaceuticals	Outperform Votes 11 47.83%	Underperform Votes 12 52.17%
NextCure	Outperform Votes 82 65.08%	Underperform Votes 44 34.92%

Is ATNM or NXTC more profitable?

NextCure's return on equity of -62.50% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
NextCure	N/A	-62.50%	-53.67%

Do institutionals and insiders hold more shares of ATNM or NXTC?

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 17.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts prefer ATNM or NXTC?

Actinium Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 141.69%. NextCure has a consensus target price of $3.50, suggesting a potential upside of 579.61%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
NextCure	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor ATNM or NXTC?

In the previous week, Actinium Pharmaceuticals had 23 more articles in the media than NextCure. MarketBeat recorded 23 mentions for Actinium Pharmaceuticals and 0 mentions for NextCure. NextCure's average media sentiment score of 0.00 beat Actinium Pharmaceuticals' score of -0.05 indicating that NextCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
NextCure	Neutral

Which has stronger earnings & valuation, ATNM or NXTC?

Actinium Pharmaceuticals has higher revenue and earnings than NextCure. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$81K	637.40	-$48.82M	-$1.39	-1.19
NextCure	N/A	N/A	-$62.72M	-$1.76	-0.29

Which has more volatility and risk, ATNM or NXTC?

Actinium Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Comparatively, NextCure has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

NextCure beats Actinium Pharmaceuticals on 10 of the 16 factors compared between the two stocks.